A Função dos Modificadores dos Leucotrienos no tratamento da Asma

Randy, J.; McGill, Kelly A.; Busse, William W.

doi:10.1016/S0873-2159(15)31055-2

Article information

Download PDF

Statistics

Full text is only aviable in PDF

BIBLIOGRAFIA

[1.]

N.C. Barnes, P.J. Piper, J.F. Costello.

Comparative effects of inhaled leucotriene C4, leukotriene D4 and histamine in normal human subjects.

Thorax, 39 (1984), pp. 500-504

Medline

[2.]

P.E. Christie, C.M. Smith, T.H. Lee.

The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma Am.

Rev. Respir. Dis., 144 (1991), pp. 957-958

[3.]

B.M. Dahlen, D.J. Kumlin, C. Larsson Margoskee, H. Blomqvist, V.C. Williams, O. Zetterstrom, S.E. Dahlen.

The leukotriene receptor antagonist Mk-0679 blocks airway obstrution induced by inhaled lysine aspirine-sensitive asthmatics.

Eur. Respir. J., 6 (1993), pp. 1018-1026

Medline

[4.]

J.R. Finnerty, H. Thomson Wood-Baker, S. Holgate.

Role of leukotrienes in exercise-induced asthma.

Am. Rev. Respir. Dis., 145 (1992), pp. 746-749

http://dx.doi.org/10.1164/ajrccm/145.4_Pt_1.746 | Medline

[5.]

E. Israel, A.R. Fisher, M.A. Rosemberg, C.M. Lilly, J.C. Callery, J. Shapiro, J. Cohn, P. Rubin, J.M. Drazen.

The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.

Am. Rev. Respir. Dis., 148 (1993), pp. 1447-1451

http://dx.doi.org/10.1164/ajrccm/148.6_Pt_1.1447 | Medline

[6.]

E.J. Israel, I. Dubé Cohn, J.M. Drazen.

Effect of tratment with zileuton, a 5- lipoxygenase inhibitor, in patients with asthma: a randomized control trial.

J.A.M.A., 275 (1996), pp. 931-936

Medline

[7.]

E.P. Rubin Israel, J.P. Kemp, J. Grossman, W. Pierson, S.C. Siegel, D. Tinkelman, J.J. Murray, W. Busse, A.T. Segal, J. Fish, H.B. Kaiser, D. LedFord, S. Wenzel, R. Rosenthal, J. Cohn, C. Lanni, H. Pearlman, P. Karahalios, J.M. Drazen.

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.

Ann. Inter. Med., 119 (1993), pp. 1059-1066

[8.]

M.C. Liu, M. Dube, J. Lancaster, Zileuton Study Group.

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial.

J. Allergy Clin. Immunol., 98 (1996), pp. 859-871

Medline

[9.]

P.J. Marnning, R.M. Watson, D.J. Margolskee, V.C. Williams, J.I. Schwartz, P.M. O'Byme.

Inhibition of exercise-induced bronchoconstrition by MK-571, a potent leukotriene D4-receptor antagonist.

N. Engl. J. Med., 323 (1990), pp. 1736-1739

http://dx.doi.org/10.1056/NEJM199012203232504 | Medline

[10.]

Meltzer SS, JD. HASDAY. J. COHN, ER. Bleecker. 1006 Inhibition of exercise induced bronchospasm by zileuton, a 5-lipoxygenase inhibitor. Am. J. Respir. Crit. Care Med. 153:931-935.

[11.]

S.L. Smith Spector, M. Glass, Accolate Asthma Trialist Group.

Effects of 6 weeks of therapy with oral doses of ICI204,219, a leukotriene D4 antagonist, in subjects with bronchial asthma.

Am. J. Respir. Crit. Care Med., 150 (1995), pp. 618-623

http://dx.doi.org/10.1164/ajrccm.150.3.8087328 | Medline

[12.]

I. O'Shaugnessy Taylor, R. Fuller, C. Dollery.

Effect of cysteinyl-leukotriene receptor antagonist ICI 204219 on allergen-induced bronchoconstrition and airway hyperactivity in atopic subjects.

Lancet, 337 (1991), pp. 690-694

Medline